Filana Therapeutics (FLNA) Share-based Compensation (2010 - 2026)

Filana Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $13.7 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 199.0% year-over-year to $13.7 million in Q2 2026; TTM through Jun 2026 was $13.7 million, a 35.26% decrease from a year earlier, with the FY2025 full-year figure at $24.5 million, down 51.58% from the prior year.
• Share-based Compensation was $13.7 million for Q2 2026 at Filana Therapeutics, down from $19.9 million in the prior quarter.
• The five-year high for Share-based Compensation was $28.9 million in Q3 2025, with the low at $616000.0 in Q4 2022.
• Average Share-based Compensation over 5 years is $6.3 million, with a median of $3.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation decreased 11.92% in 2023, then soared 415.24% in 2025.
• Over 5 years, Share-based Compensation stood at $616000.0 in 2022, then surged by 245.62% to $2.1 million in 2023, then surged by 169.8% to $5.7 million in 2024, then declined by 6.44% to $5.4 million in 2025, then surged by 154.93% to $13.7 million in 2026.
• The last three Share-based Compensation figures came in at $13.7 million (Q2 2026), $19.9 million (Q1 2026), and $5.4 million (Q4 2025), per Business Quant data.